tenant profile: syNpromics ltd

We are pleased to welcome Synpromics Ltd, one of the UK’s most innovative companies working in gene medicine and an ideal fit for our tenant profile, to customised office and lab space at Roslin Innovation Centre.

Synpromics logo

Synpromics Ltd is the leader in gene control and synthetic promoter development.

The company is expanding to meet increasing global demand for its cutting-edge gene control technology. 

To facilitate the development and commercialisation of synthetic promoters for gene and cell therapy products and bioprocess applications, the company will occupy both labs and open plan offices at Roslin Innovation Centre and has recently established a new US subsidiary, Synpromics Inc. 

“Roslin Innovation Centre offers genuine opportunities for leading innovation companies to be part of an integrated and collaborative community and we very much look forward to engaging further with Synpromics.”

"Synpromics’ innovation has been attracting attention within the life sciences community and we look forward to providing an environment conducive for the business to realise its long-term growth ambition.”

John Mackenzie, CEO, Roslin Innovation Centre

“Our move to Roslin is the result of two incredibly successful years for the company. Over that time Synpromics’ team has grown by over 100% and is one of our greatest assets. We look forward to working in our new high tech facilities as we continue to build the company for the future.” 

David Venables, CEO,Synpromics

Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design. The company has developed PromPT™, its multi-dimensional bioinformatics database that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications. 

The company operates in a diverse range of fields, including broad applications in cell and gene based medicine, biologics manufacturing and viral vector bioprocessing. 

Current partners include Adverum, uniQure, AGTC, GE Healthcare, and Sartorius-Stedim Cellca as well as numerous undisclosed partners in the pharmaceutical sector. 

Naturally occurring promoters have evolved for biological functions but have limitations when utilised in industrial or therapeutic applications. Synthetic promoters with DNA sequences not found in nature are designed to better regulate gene activity and precisely control protein production. Synpromics creates highly specific promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. Each synthetic promoter represents a novel invention and thus can be patented.

Dr David Venables, CEO
Synpromics Ltd

Roslin Innovation Centre
University of Edinburgh
Easter Bush Campus
Midlothian, EH25 9RG

T: +44 (0)7825 323439
E: David.Venables@synpromics.com